Simmons Bank Has $2.16 Million Holdings in GSK PLC Sponsored ADR (NYSE:GSK)

Simmons Bank lessened its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 63.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 55,770 shares of the pharmaceutical company's stock after selling 95,552 shares during the period. Simmons Bank's holdings in GSK were worth $2,161,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Brighton Jones LLC acquired a new stake in GSK during the 4th quarter valued at $528,000. Bank of New York Mellon Corp grew its stake in shares of GSK by 2.2% during the fourth quarter. Bank of New York Mellon Corp now owns 974,051 shares of the pharmaceutical company's stock valued at $32,942,000 after acquiring an additional 20,659 shares in the last quarter. SRS Capital Advisors Inc. grew its stake in shares of GSK by 51.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,414 shares of the pharmaceutical company's stock valued at $48,000 after acquiring an additional 480 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of GSK by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 126,647 shares of the pharmaceutical company's stock worth $4,283,000 after acquiring an additional 5,044 shares during the last quarter. Finally, Assetmark Inc. lifted its stake in shares of GSK by 279.6% in the fourth quarter. Assetmark Inc. now owns 75,149 shares of the pharmaceutical company's stock worth $2,542,000 after acquiring an additional 55,354 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

NYSE GSK traded up $0.03 on Monday, reaching $38.21. 3,865,816 shares of the stock traded hands, compared to its average volume of 4,934,908. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.67. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.21. The firm's fifty day simple moving average is $39.00 and its 200 day simple moving average is $37.14. The company has a market cap of $78.23 billion, a price-to-earnings ratio of 19.70, a P/E/G ratio of 1.53 and a beta of 0.50.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.05. GSK had a return on equity of 48.82% and a net margin of 9.89%. The company had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. During the same quarter in the prior year, the company earned $0.43 earnings per share. The firm's revenue was up 2.1% on a year-over-year basis. As a group, research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. The ex-dividend date is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.41%. This is a positive change from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 87.11%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GSK. BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Finally, Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.